The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study.
 
Nethanel Asher
Honoraria - BMS GmbH & Co. KG; Medison; MSD Oncology; Novartis; Sanofi; Taro
 
Peter Mohr
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma Advanced Research Company
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis Deutschland LTd (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sun Pharma
 
Eva Ellebaek
Honoraria - Bristol Myers Squibb Foundation; Merck; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Merck; Pierre Fabre
 
Marc Bender
No Relationships to Disclose
 
Joanna Mangana
Honoraria - BMS; MSD
Consulting or Advisory Role - BMS; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - BMS (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Pierre Fabre
 
Lidija Kandolf
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; MSD Oncology; Novartis; Pfizer/EMD Serono; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Iva Gavrilova
Honoraria - Medisonpharma; MSD, Roche, Merck, Novartis, BMS, Sanofi; Pierre Fabre
Consulting or Advisory Role - Medisonpharma; MSD, Roche, Merck, Novartis, BMS, Sanofi; Pierre Fabre
Speakers' Bureau - Medisonpharma; MSD, Roche, Merck, Novartis, BMS, Sanofi; pierre fabre
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Sanofi
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Lars Bastholt
No Relationships to Disclose
 
Michael Weichenthal
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)